Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

July 18, 2022

Cosela May Decrease Chemo-Related Blood Complications During Lung Cancer Treatment

Author(s):

Brielle Benyon

Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.

Patients with extensive-stage small cell lung cancer tended to have fewer myelosuppressive events, when they received Cosela (trilaciclib) before chemotherapy, according to findings from phase 2 clinical trials.

“Myelosuppression is a major toxicity of chemotherapy treatment for patients with extensive-stage small cell lung cancer that often results in chemotherapy dose delays and dose reductions, both of which can compromise clinical outcomes,” Dr. Jerome Goldschmidt, medical oncologist with Blue Ridge Cancer Care in Blacksburg, VA, and lead study author, said in a press release.

Myelosuppression happens when activity in the bone marrow is decreased, which leads to fewer red and white blood cells, as well as platelets. The toxicity is commonly seen in patients taking certain chemotherapy agents, and can cause fever, chills, extreme fatigue, easy bruising and other side effects.

Read more: ‘A Breath of Fresh Air’: FDA’s Cosela Approval May Improve Quality of Life in Lung Cancer

In particular, Cosela decreased the following myelosuppressive events: severe neutropenia (when there are too few neutrophils, which are a type of white blood cell), anemia (too few red blood cells) and thrombocytopenia (too few platelets in the blood).

When given in the frontline setting for patients with extensive-stage small cell lung cancer, Cosela led to:

  • 75% reduction in severe neutropenia (56.7% with placebo, compared to 14.4% with Cosela)
  • 50% reduction in severe anemia (17.8% versus 8.9%)
  • 100% reduction in severe thrombocytopenia (12.2% versus 0%)

The drug also led to a decrease in concurrent (happening simultaneously or overlapping for at least one day) myelosuppressive events. Study findings showed:

  • 100% reduction in severe anemia, neutropenia and thrombocytopenia (2.2% with placebo compared to 0% with Cosela)
  • 100% reduction in severe neutropenia and thrombocytopenia (13.3% versus 0%)
  • 50% reduction in severe neutropenia and anemia (94.4% versus 2.2%)
  • 33% reduction in severe anemia and thrombocytopenia (3.3% versus 2.2%)

“Both the patients and the healthcare system at large bear the complications of myelosuppressive events such as neutropenia, anemia and thrombocytopenia, so it is imperative that we achieve clinically meaningful reductions in myelosuppression in multiple cell lineages and its consequences utilizing novel therapies such as Cosela,” Goldschmid said.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
Image of a woman wearing a headband and glasses
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Image of woman.
Image of Doctor.
Image of doctor with black hair.
Related Content
Advertisement
Image of lungs.
May 21st 2025

FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer

Spencer Feldman
ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of lungs.
May 15th 2025

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

Ryan Scott
The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text
May 14th 2025

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

Ryan Scott
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.
Investigators are using MET immunohistochemistry testing to address unmet needs in NSCLC treatment: © stock.adobe.com.
May 12th 2025

IHC Testing Aims to Expand Personalized Treatment in Lung Cancer

Ryan Scott
Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.
Related Content
Advertisement
Image of lungs.
May 21st 2025

FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer

Spencer Feldman
ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of lungs.
May 15th 2025

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

Ryan Scott
The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text
May 14th 2025

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

Ryan Scott
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.
Investigators are using MET immunohistochemistry testing to address unmet needs in NSCLC treatment: © stock.adobe.com.
May 12th 2025

IHC Testing Aims to Expand Personalized Treatment in Lung Cancer

Ryan Scott
Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.